Pharmaceutical Company SmartScripts Pays Over $132,000 in Ozempic Counterfeit Settlement
Washington-based SmartScripts completed a payment of $132,873.60 today to Michigan’s Central Pharmacy Management (CPM) following a settlement regarding the sale of counterfeit Ozempic, a medication used to treat type 2 diabetes and, increasingly, for weight loss.
Court records show CPM initially filed a claim alleging SmartScripts sold them illegitimate Ozempic. Following notification from a Food and Drug Administration officer confirming the drugs were counterfeit, CPM was ordered to halt sales. The settlement fully reimbursed CPM the $132,249.46 originally charged for the medication, plus accrued interest and associated court costs. The payment was finalized on October 28, 2025.
This case highlights growing concerns about the safety and authenticity of medications, particularly those experiencing high demand like Ozempic. In a separate action this past August, the Iowa Board of Pharmacy penalized SmartScripts with a $25,000 fine and placed the company on a five-year probation period regarding its pharmacy license. You can find more information about counterfeit medications from the FDA.
Officials have not yet commented on whether further investigations are planned, but the incident serves as a reminder for pharmacies to verify the legitimacy of their drug suppliers. For more on pharmaceutical regulations, see the American Society of Health-System Pharmacists.
